FOLD

Amicus Therapeutics Inc

Add to Watchlist

Advanced Chart

6.060

-0.22(-3.503%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

6.290

Open

6.270

VWAP

6.05

Vol

3.51M

Mkt Cap

1.87B

Low

5.970

Amount

21.20M

EV/EBITDA(TTM)

35.81

Total Shares

296.20M

2.01B

EV/OCF(TTM)

563.22

P/S(TTM)

3.41

Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

182.46M

+21.88%

164.24M

+16.06%

146.68M

+15.8%

Estimates Revision

The market is revising Downward the revenue expectations for Amicus Therapeutics, Inc. (FOLD) for FY2025, with the revenue forecasts being adjusted by -1.48% over the past three months. During the same period, the stock price has changed by -18.00%.

Revenue Estimates for FY2025

Revise Downward

-1.48%

In Past 3 Month

Stock Price

Go Down

-18.00%

In Past 3 Month

7 Analyst Rating

180.53% Upside

Wall Street analysts forecast FOLD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FOLD is 17.00 USD with a low forecast of 13.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

180.53% Upside

Current: 6.060

Low

13.00

Averages

17.00

High

22.00

180.53% Upside

Current: 6.060

Low

13.00

Averages

17.00

High

22.00

Morgan Stanley

Equal Weight -> Overweight

upgrade

$12

2025-07-16

Reason

Morgan Stanley

Price Target

$12

2025-07-16

upgrade

Equal Weight -> Overweight

Reason

Morgan Stanley upgraded Amicus to Overweight from Equal Weight with a $12 price target.

Morgan Stanley

Equal Weight -> Overweight

upgrade

$102 -> $108

2025-07-16

Reason

Morgan Stanley

Price Target

$102 -> $108

2025-07-16

upgrade

Equal Weight -> Overweight

Reason

Morgan Stanley upgraded Amicus to Overweight from Equal Weight with a price target of $108, up from $102. The firm said it the upgrade is based on its favorable view of Amicus' intellectual property position heading into summary judgment with Aurobindo and longer term confidence in patients switching from Nexviazyme/Lumizyme to PomOp. The firm also noted that the Q1 miss was driven by order timing and the higher UK Voluntary Scheme for Branded Medicines Pricing and Access rebate rate of 22%, compared to the anticipated 12%-15%, reflected in the updated guidance.

Needham

Gil Blum

Hold

Reiterates

n/a

2025-02-20

Reason

Needham

Gil Blum

Price Target

n/a

2025-02-20

Reiterates

Hold

Reason

Wells Fargo

Tiago Fauth

Buy

Maintains

$18 → $17

2025-02-20

Reason

Wells Fargo

Tiago Fauth

Price Target

$18 → $17

2025-02-20

Maintains

Buy

Reason

Wells Fargo analyst Tiago Fauth lowered the firm's price target on Amicus to $17 from $18 and keeps an Overweight rating on the shares. The firm notes the company reported fairly in-line earnings, with no material updates vs pre-announcement. PomOp launch remains the focus of the stock and Amicus continues to execute well with Australia approval recently granted.

Cantor Fitzgerald

Kristen Kluska

Buy

Reiterates

$21

2025-01-15

Reason

Cantor Fitzgerald

Kristen Kluska

Price Target

$21

2025-01-15

Reiterates

Buy

Reason

Needham

Gil Blum

Hold

Reiterates

n/a

2025-01-13

Reason

Needham

Gil Blum

Price Target

n/a

2025-01-13

Reiterates

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Amicus Therapeutics Inc (FOLD.O) is -168.33, compared to its 5-year average forward P/E of -2.50. For a more detailed relative valuation and DCF analysis to assess Amicus Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.50

Current PE

-168.33

Overvalued PE

121.47

Undervalued PE

-126.47

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

36.96

Current EV/EBITDA

26.14

Overvalued EV/EBITDA

183.73

Undervalued EV/EBITDA

-109.81

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

7.93

Current PS

2.95

Overvalued PS

11.35

Undervalued PS

4.52

Financials

Annual

Quarterly

FY2025Q1

YoY :

+13.45%

125.25M

Total Revenue

FY2025Q1

YoY :

-63.31%

-7.95M

Operating Profit

FY2025Q1

YoY :

-55.21%

-21.69M

Net Income after Tax

FY2025Q1

YoY :

-56.25%

-0.07

EPS - Diluted

FY2025Q1

YoY :

-123.95%

7.55M

Free Cash Flow

FY2025Q1

YoY :

+4.00%

89.19

Gross Profit Margin - %

FY2025Q1

YoY :

-101.44%

0.30

FCF Margin - %

FY2025Q1

YoY :

-60.53%

-17.31

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

4.0K

USD

6-9

Months

259.9K

USD

0-12

Months

167.3K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

5.5M

Volume

6-9

Months

5.0M

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

3.7M

Volume

Months

6-9

3.4M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

4.0K

USD

6-9

Months

259.9K

USD

0-12

Months

167.3K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

FOLD News & Events

Events Timeline

2025-06-25 (ET)

2025-06-25

07:08:43

Amicus announces approval of Pombiliti + Opfolda in Japan

2025-06-03 (ET)

2025-06-03

07:06:10

Amicus announces publication of post-hoc analysis of data from PROPEL study

2025-05-01 (ET)

2025-05-01

07:07:12

Amicus lowers FY25 total revenue growth view 15%-22% from 17%-24%

News

6.0

07-17SeekingAlpha

Amicus gains as Morgan Stanley upgrades on Aurobindo case and Pom-Op switching

7.0

07-10PRnewswire

SHAREHOLDER NOTICE: Kaskela Law LLC Announces Shareholder Investigation of Amicus Therapeutics, Inc. (NASDAQ: FOLD) and Encourages Long-Term FOLD Investors to Contact the Firm

9.0

06-25Newsfilter

Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan